RT Journal Article
SR Electronic
T1 SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.03.14.988345
DO 10.1101/2020.03.14.988345
A1 Ke Wang
A1 Wei Chen
A1 Yu-Sen Zhou
A1 Jian-Qi Lian
A1 Zheng Zhang
A1 Peng Du
A1 Li Gong
A1 Yang Zhang
A1 Hong-Yong Cui
A1 Jie-Jie Geng
A1 Bin Wang
A1 Xiu-Xuan Sun
A1 Chun-Fu Wang
A1 Xu Yang
A1 Peng Lin
A1 Yong-Qiang Deng
A1 Ding Wei
A1 Xiang-Min Yang
A1 Yu-Meng Zhu
A1 Kui Zhang
A1 Zhao-Hui Zheng
A1 Jin-Lin Miao
A1 Ting Guo
A1 Ying Shi
A1 Jun Zhang
A1 Ling Fu
A1 Qing-Yi Wang
A1 Huijie Bian
A1 Ping Zhu
A1 Zhi-Nan Chen
YR 2020
UL http://biorxiv.org/content/early/2020/03/14/2020.03.14.988345.abstract
AB Currently, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely spread around the world; nevertheless, so far there exist no specific antiviral drugs for treatment of the disease, which poses great challenge to control and contain the virus. Here, we reported a research finding that SARS-CoV-2 invaded host cells via a novel route of CD147-spike protein (SP). SP bound to CD147, a receptor on the host cells, thereby mediating the viral invasion. Our further research confirmed this finding. First, in vitro antiviral tests indicated Meplazumab, an anti-CD147 humanized antibody, significantly inhibited the viruses from invading host cells, with an EC50 of 24.86 μg/mL and IC50 of 15.16 μg/mL. Second, we validated the interaction between CD147 and SP, with an affinity constant of 1.85×10−7M. Co-Immunoprecipitation and ELISA also confirmed the binding of the two proteins. Finally, the localization of CD147 and SP was observed in SARS-CoV-2 infected Vero E6 cells by immuno-electron microscope. Therefore, the discovery of the new route CD147-SP for SARS-CoV-2 invading host cells provides a critical target for development of specific antiviral drugs.